アメリカ知財情報サイト

カナダにおける新しい特許期限延長システム(医薬品限定)

カナダでヨーロッパとの通商条約に伴い、新たな特許延長システムがはじまりました。これは医薬品の開発時間と行政の認証にかかる時間の一部を補う目的で作られました。ヨーロッパの仕組みと似ていますが、いくつか違いもあり、特に、延長期間が最大で2年までとされている点が大きな違いです。

以下が概要です:

Feature Details
Protection
  • CSP.
Governing legislation
  • Patent Act (Sections 104 to 134).
  • CSP Regulations.
Guidance
  • Health Canada guidance document.
Register
  • Register of CSPs and Applications.
Drugs covered
  • Human small molecules.
  • Biologics.
  • Veterinary small molecules.
Term
  • From patent application filing date until notice of compliance (NOC) date, minus five years.
  • Capped at two years.
Paediatric extension
  • Not applicable.
Reduction in term
  • Possible if the NOC holder is also the patentee and the failure to act resulted in an unjustified delay in obtaining the NOC.
Eligible patent
  • Patent must include:
    • a product or product-by-process claim for the medicinal ingredient or combination of medicinal ingredients contained in an approved drug; or
    • a use thereof (whether the claimed use is approved or not).
Scope of protection
  • Same rights as for patents, but only with respect to the use, among other things, of “any drug that contains the medicinal ingredient, or combination of medicinal ingredients [and prescribed variations thereof], set out in the certificate, by itself or in addition to any other medicinal ingredient”.
  • As an exception, CSPs do not apply to use, among other things, for export.
Assertable under Linkage Regulations
  • Yes – Patented Medicines (Notice of Compliance) Regulations.
Where application filed
  • Health Canada.
Deadline for filing application
  • Within 120 days from the later of the NOC date or the patent grant date.
Deadline for filing regulatory submission
  • One year from first regulatory submission filing for the medicinal ingredient or combination of medicinal ingredients in:
    • the European Union or any member country thereof;
    • the United States;
    • Australia;
    • Switzerland; or
    • Japan.
  • This is subject to a transitional provision of two years if the CSP application is filed by September 21 2018.
Protection by basic patent in force requirement
  • Not applicable.
First NOC/marketing authorisation requirement
  • A CSP application must be based on the first NOC (human or veterinary, as applicable) for the medicinal ingredient, combination of medicinal ingredients or prescribed variations thereof, provided that the NOC was granted on or after September 21 2017. Prior approvals for regular sale other than NOCs also preclude a CSP.
Number of CSPs per drug product
  • One.
Third-party filing
  • Yes, third-party filing is possible (ie, the patentee-applicant need not be the holder of the NOC and patentees can authorise the holder of an NOC to file on its behalf).
Priority determinations
  • Patent Act (Sections 108 to 111).
  • CSP Regulations (Section 11).
  • The highest priority is given to applications for patents granted on or before the NOC date.
Consideration of third-party observations during pendency of application review
  • It remains unclear whether Health Canada will consider any such observations.
Declaration of invalidity of CSP application/CSP
  • The Federal Court may declare a pending CSP application (only in the instance of another CSP application based on the same NOC and having same priority) or a CSP void.

まとめ作成者:野口剛史

元記事著者:Nancy Pei. Smart & Biggar/Fetherstonhaugh(元記事を見る

OLCの米国知財ニュースレター

最新まとめ記事を
毎週メールボックスにお届け

登録すると、週1回、最新まとめ記事の概要とお知らせを受け取ることができます。

コメントする

次回ウェビナー

8月31日開催予定

FRUSTRATION FREE EMAIL COMMUNICATION

OLCとは?

OLCは、「アメリカ知財をもっと身近なものにしよう」という思いで作られた日本人のためのアメリカ知財情報提供サイトです。より詳しく>>

追加記事

track-start-line
特許出願
野口 剛史

生命科学の発明を特許出願する前に公開してもいいのか?

生命科学の分野では特に、なるべく早く発明を発表し、発見を公開する傾向があります。しかし、学術的に一番いい方法が必ずしもビジネスにおいて最適だとは限りません。ほとんどの国では、特許出願の前に発明を公開してしまうと、特許が取得できなくなってしまいます。つまり、アカデミアの意識のままの発明者がいると、雇っている会社にとって大きな打撃になってしまう可能性がります。

Read More »